This patent allowance is a routine IP event for a pre-revenue clinical-stage biotech with a $3M market cap. No financial data or clinical catalysts are provided. Monitor for future partnering announcements or clinical trial updates on IM1240, but the filing itself does not warrant a trading action.
Price Chart
Executive Summary
Purple Biotech announced a USPTO Notice of Allowance for a patent covering tri-specific antibody constructs and methods of use, strengthening IP protection for its CAPTN-3 modular platform. This is a routine IP milestone for a clinical-stage company with a $3M market cap and no revenue, providing no near-term financial catalyst. Historical performance on this ticker shows poor calibration with significant negative average returns on prior reports, warranting a neutral stance.
Key Facts
- USPTO issued Notice of Allowance for patent application covering tri-specific antibody constructs and methods of use.
- Patent strengthens IP protection for CAPTN-3 modular platform for conditionally activated multispecific antibodies.
- Lead candidate IM1240 is advancing toward the clinic; second candidate IM1305 is in preclinical development.
- Company market cap is approximately $3M with no reported revenue from the filing.
Financial Impact
No financial figures disclosed; patent allowance is an IP milestone with no immediate revenue or cost impact.
Risk Factors
- No revenue or near-term commercialization path disclosed.
- Lead candidate IM1240 is still pre-clinical; clinical-stage assets (CM24, NT219) require partnering or investment to advance.
- Historical reports on PPBT show poor calibration with significant negative average returns at T+20.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-096443 |
| Document: ea0304192-6k_purple.htm | 0001213900-26-096443 |
| Document: 0001213900-26-096443-index-headers.html | 0001213900-26-096443 |
| Document: 0001213900-26-096443-index.html | 0001213900-26-096443 |
| Document: 0001213900-26-096443.txt | 0001213900-26-096443 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 6-K | $1.74 $1.55 | ▼ −11.21% | ▼ −10.71% | $1.44 (−17.24%) |
Sep 2, 2026 4w ago | 6-K | $1.98 $1.74 | ▼ −12.12% | ▼ −11.16% | $1.44 (−27.27%) |
Aug 10, 2026 7w ago | 6-K | $1.55 $1.56 | ▲ +0.65% | ▲ +1.05% | $1.44 (−7.10%) |
Aug 7, 2026 8w ago | 6-K | $1.43 $1.50 | ▲ +4.90% | ▲ +4.50% | $1.44 (+0.70%) |
May 15, 2026 20w ago | Press Release | $3.94 $2.88 | ▼ −26.90% | ▼ −27.87% | $1.44 (−63.45%) |
Apr 27, 2026 22w ago | 6-K | $4.59 $4.22 | ▼ −8.06% | ▼ −8.46% | $1.44 (−68.63%) |
Apr 23, 2026 23w ago | 6-K | $4.55 $4.23 | ▼ −7.03% | ▼ −8.51% | $1.44 (−68.35%) |
Mar 13, 2026 29w ago | Press Release | $4.10 $3.98 | ▼ −2.93% | ▼ −0.81% | $1.44 (−64.88%) |
Mar 13, 2026 29w ago | Press Release | $4.10 $3.98 | ▼ −2.93% | ▼ −0.81% | $1.44 (−64.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access